Gates Foundation hires Apple digital health expertThe Bill & Melinda Gates Foundation has snapped up one of Apple’s digital health gurus, Dr Andrew Trister, Share XGates Foundation hires Apple digital health experthttps://pharmaphorum.com/news/gates-foundation-hires-apple-digital-health-expert/
FDA approves Roche’s “tumour agnostic” drug RozlytrekThe FDA has approved Roche’s Rozlytrek (entrectinib), a so-called “tumour agnostic” drug that is approved to key into certain mutations in Share XFDA approves Roche’s “tumour agnostic” drug Rozlytrekhttps://pharmaphorum.com/news/fda-approves-roches-tumour-agnostic-drug-rozlytrek/
Scotland’s cost regulator rejects Vertex cystic fibrosis drugsScotland’s cost-effectiveness body has rejected regular NHS funding for Vertex’s cystic fibrosis drugs Orkambi and Symkevi because of Share XScotland’s cost regulator rejects Vertex cystic fibrosis drugshttps://pharmaphorum.com/news/scotlands-cost-regulator-rejects-vertex-cystic-fibrosis-drugs/
Regeneron preps for 2020 filing for new cholesterol drug after trial successRegeneron has announced data that could create a niche for its latest cholesterol drug evinacumab in a small Share XRegeneron preps for 2020 filing for new cholesterol drug after trial successhttps://pharmaphorum.com/news/evinacumab-regeneron-cholesterol-drug-trial/
Novartis axed Avexis execs ahead of Zolgensma scandalThe plot thickens at Novartis, which is becoming embroiled in a scandal over falsification of data related to Share XNovartis axed Avexis execs ahead of Zolgensma scandalhttps://pharmaphorum.com/news/novartis-axed-avexis-execs-ahead-of-zolgensma-scandal/
Astellas tests gamification ideas with Japanese universitiesAstellas has teamed up with Tokyo University of the Arts and Yokohama City University to create and commercialise Share XAstellas tests gamification ideas with Japanese universitieshttps://pharmaphorum.com/news/astellas-tests-gamification-ideas-with-japanese-universities/
AbbVie/Janssen win EU approval for two new Imbruvica usesEuropean regulators have approved AbbVie and Janssen’s Imbruvica (ibrutinib) in two expanded uses that broaden the use of Share XAbbVie/Janssen win EU approval for two new Imbruvica useshttps://pharmaphorum.com/news/eu-regulators-approve-two-new-uses-for-janssens-imbruvica/
Pharming buys rare disease drug from Novartis for $20mPharming has bought a late-stage pipeline drug aimed at a rare disease of the immune system from Novartis Share XPharming buys rare disease drug from Novartis for $20mhttps://pharmaphorum.com/news/pharming-buys-rare-disease-drug-from-novartis-for-20m/
NHS patients to receive digital diabetes prevention supportThousands of patients at risk of type 2 diabetes are to receive digital support to help prevent them Share XNHS patients to receive digital diabetes prevention supporthttps://pharmaphorum.com/news/nhs-patients-to-receive-digital-diabetes-support/
AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatmentAstraZeneca and MSD’s Lynparza has scored its second Phase 3 win in the space of a week, this Share XAZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatmenthttps://pharmaphorum.com/news/az-msd-parp-inhibitor-ovarian-cancer/
McCann Health promotes Hilary Gentile to global chief strategy officerMcCann Health has promoted Hilary Gentile to the newly created position of global chief strategy officer. Hilary has Share XMcCann Health promotes Hilary Gentile to global chief strategy officerhttps://pharmaphorum.com/news/mccann-health-promotes-hilary-gentile-to-global-chief-strategy-officer/
First effective Ebola treatment a step closer after breakthrough trialClinical trials of four experimental treatments for Ebola in the Congo have been halted early after two of Share XFirst effective Ebola treatment a step closer after breakthrough trialhttps://pharmaphorum.com/news/ebola-virus-clinical-trial-breakthrough/
LIVI expands reach for its NHS GP consultation mobile appDigital healthcare firm LIVI has signed new agreements with the NHS that will open up access to its Share XLIVI expands reach for its NHS GP consultation mobile apphttps://pharmaphorum.com/news/nhs-gp-consultation-app-expanded/
GSK announces US leadership changesGlaxoSmithKline has poached Merck KGaA’s Maya Martinez-Davis to head up its US Pharmaceuticals division as it announces current Share XGSK announces US leadership changeshttps://pharmaphorum.com/news/gsk-announces-us-leadership-changes/
US senators blast Novartis for Zolgensma data falsificationUS politicians have urged the FDA to come down hard on Novartis for failing to disclose manipulated data Share XUS senators blast Novartis for Zolgensma data falsificationhttps://pharmaphorum.com/news/us-senators-blast-novartis-for-zolgensma-data-falsification/
Boehringer jumps on KRAS cancer drug bandwagon with MD AndersonBoehringer Ingelheim has become the latest pharma company to investigate KRAS as a potential target for cancer drugs, Share XBoehringer jumps on KRAS cancer drug bandwagon with MD Andersonhttps://pharmaphorum.com/news/boehringer-jumps-on-kras-cancer-drug-bandwagon-with-md-anderson/
Hikma buys potential Epipen rival from troubled InsysUK-based pharma Hikma has snapped up assets from embattled Insys Therapeutics, including potential generics of Mylan’s Epipen allergic Share XHikma buys potential Epipen rival from troubled Insyshttps://pharmaphorum.com/news/hikma-buys-potential-epipen-generic-from-insys/
AZ’s lung cancer drug Tagrisso gets boost from first line OS resultsAstraZeneca has announced figures confirming that its Tagrisso extends overall survival in patients with untreated non-small cell lung Share XAZ’s lung cancer drug Tagrisso gets boost from first line OS resultshttps://pharmaphorum.com/news/azs-key-cancer-drug-tagrisso-gets-further-boost-from-os-results/
Registration is now open for the Pre-filled Syringes and Injectable devices Conference Share XRegistration is now open for the Pre-filled Syringes and Injectable devices Conferencehttps://pharmaphorum.com/partner-content/registration-is-now-open-for-the-pre-filled-syringes-and-injectable-devices-conference/
NICOX discusses New Glaucoma Treatment at SMi’s 3rd Ophthalmic Drugs Conference Share XNICOX discusses New Glaucoma Treatment at SMi’s 3rd Ophthalmic Drugs Conferencehttps://pharmaphorum.com/partner-content/nicox-discusses-new-glaucoma-treatment-at-smis-3rd-ophthalmic-drugs-conference/
DTC Genetic Testing Market will cross $2,500 million by 2025 Share XDTC Genetic Testing Market will cross $2,500 million by 2025https://pharmaphorum.com/partner-content/dtc-genetic-testing-market-will-cross-2500-million-by-2025/
Cannabis Testing Market will surpass $2,000 million by 2025 Share XCannabis Testing Market will surpass $2,000 million by 2025https://pharmaphorum.com/partner-content/cannabis-testing-market-will-surpass-2000-million-by-2025/
Ashfield Commercial and Patient Solutions appoints President of Global Business Development Share XAshfield Commercial and Patient Solutions appoints President of Global Business Developmenthttps://pharmaphorum.com/partner-content/ashfield-commercial-and-patient-solutions-appoints-president-of-global-business-development/
Alice Choi appointed HCA chairperson Share XAlice Choi appointed HCA chairpersonhttps://pharmaphorum.com/news/alice-choi-hca-chairperson/
